Tasha Borget has contributed to the HerediGene:Population Study.
When Tasha Borget participated in the HerediGene: Population Study, she trusted her contribution would mean more than just the healthcare answers she needed.
Tasha, 29, never knew her birth father so there are many holes in her family medical history. As a medical professional she knows this family history is important in determining whether she may be at risk of hereditary diseases.
“I always have those questions,” Tasha says. “Working in the medical field, I know the difference it could make.”
Genetic screening and research can improve prediction, prevention, and treatment. That’s where Tasha knew she could play a part. By joining the HerediGene: Population Study, Tasha could help not only herself, but her family and generations of other families across the globe beat hereditary disease.
“This study gave me the opportunity to learn if there are any underlying medical conditions that contribute to my health,” Tasha says. “Whether I get results back or not, I know I’m contributing to the research that can make solutions a possibility for people in the future. I think that’s something we can all do as citizens for a healthier community.”
You, too, can sign up for the HerediGene: Population Study by going to HerediGene.org. Any U.S. resident is eligible. Participation is voluntary and offered at no cost to you. When you sign up online, a HerediGene order will be automatically generated in iCentra. Then, visit any Intermountain lab or draw station to have two tubes of blood drawn for the study.
Tasha donated blood at the outpatient lab located inside St. George Regional Hospital. This lab is one of almost 50 locations where participants can give blood after signing up online.
Tasha’s blood sample joins the more than 60,000 deidentified samples researchers are studying to further improve healthcare for patients with hereditary disease.
In rare cases, HerediGene participants may directly benefit from the study by receiving results on genetic variants that we can treat. Only about 3% of the half-million sampled may be contacted with results about a known and treatable genetic condition. Most participants won’t be contacted with results from the study.
“We’re mapping the genomes of participants to directly impact their care,” says Lincoln Nadauld, MD, PhD, Intermountain’s vice president and chief of Precision Health and Academics and the study’s principal investigator. “We want to know if you’re at risk of cancer, cardiovascular disease, or neurodegenerative disorders. We want to help you avoid those conditions. We want to predict what healthcare events might happen and we want to prevent those from happening, for you and for future generations.”
Thanks to participants like Tasha, we’re closer than ever to preventing hereditary disease and helping patients live longer, better lives, he says. You’re invited to participant and make a difference.
To join the HerediGene: Population Study, visit HerediGene.org. Then, donate a blood sample to the study at any Intermountain outpatient lab. Children ages 17 and younger may participate at Primary Children’s Hospital. If you choose to join the study, your contribution may help inform the kinds of discoveries that improve healthcare for all.
Leave a comment on Yammer.
Tasha, 29, never knew her birth father so there are many holes in her family medical history. As a medical professional she knows this family history is important in determining whether she may be at risk of hereditary diseases.
“I always have those questions,” Tasha says. “Working in the medical field, I know the difference it could make.”
Genetic screening and research can improve prediction, prevention, and treatment. That’s where Tasha knew she could play a part. By joining the HerediGene: Population Study, Tasha could help not only herself, but her family and generations of other families across the globe beat hereditary disease.
“This study gave me the opportunity to learn if there are any underlying medical conditions that contribute to my health,” Tasha says. “Whether I get results back or not, I know I’m contributing to the research that can make solutions a possibility for people in the future. I think that’s something we can all do as citizens for a healthier community.”
You, too, can sign up for the HerediGene: Population Study by going to HerediGene.org. Any U.S. resident is eligible. Participation is voluntary and offered at no cost to you. When you sign up online, a HerediGene order will be automatically generated in iCentra. Then, visit any Intermountain lab or draw station to have two tubes of blood drawn for the study.
Tasha donated blood at the outpatient lab located inside St. George Regional Hospital. This lab is one of almost 50 locations where participants can give blood after signing up online.
Tasha’s blood sample joins the more than 60,000 deidentified samples researchers are studying to further improve healthcare for patients with hereditary disease.
In rare cases, HerediGene participants may directly benefit from the study by receiving results on genetic variants that we can treat. Only about 3% of the half-million sampled may be contacted with results about a known and treatable genetic condition. Most participants won’t be contacted with results from the study.
“We’re mapping the genomes of participants to directly impact their care,” says Lincoln Nadauld, MD, PhD, Intermountain’s vice president and chief of Precision Health and Academics and the study’s principal investigator. “We want to know if you’re at risk of cancer, cardiovascular disease, or neurodegenerative disorders. We want to help you avoid those conditions. We want to predict what healthcare events might happen and we want to prevent those from happening, for you and for future generations.”
Thanks to participants like Tasha, we’re closer than ever to preventing hereditary disease and helping patients live longer, better lives, he says. You’re invited to participant and make a difference.
To join the HerediGene: Population Study, visit HerediGene.org. Then, donate a blood sample to the study at any Intermountain outpatient lab. Children ages 17 and younger may participate at Primary Children’s Hospital. If you choose to join the study, your contribution may help inform the kinds of discoveries that improve healthcare for all.
Leave a comment on Yammer.